Maravai LifeSciences (NASDAQ:MRVI) Posts Earnings Results, Misses Expectations By $0.01 EPS

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01), Briefing.com reports. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The company had revenue of $46.85 million during the quarter, compared to the consensus estimate of $44.01 million. The company's revenue was down 26.9% compared to the same quarter last year. Maravai LifeSciences updated its FY 2025 guidance to EPS.

Maravai LifeSciences Stock Up 7.1%

Shares of MRVI traded up $0.14 during mid-day trading on Friday, reaching $2.10. The company's stock had a trading volume of 1,860,282 shares, compared to its average volume of 2,348,867. The company has a market cap of $534.11 million, a price-to-earnings ratio of -1.28 and a beta of 0.19. The business has a fifty day moving average of $2.09 and a 200 day moving average of $4.03. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. Maravai LifeSciences has a 1 year low of $1.67 and a 1 year high of $11.50.

Analysts Set New Price Targets

MRVI has been the topic of several research analyst reports. Stifel Nicolaus set a $5.00 price target on Maravai LifeSciences in a research report on Friday, March 21st. Baird R W cut shares of Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Robert W. Baird reduced their price objective on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday. UBS Group lowered their price objective on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Finally, Craig Hallum cut their target price on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $6.64.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.